Zacks Investment Research Downgrades Deciphera Pharmaceuticals (DCPH) to Hold

Deciphera Pharmaceuticals (NASDAQ:DCPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Monday.

According to Zacks, “Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States. “

A number of other equities analysts also recently issued reports on the company. BidaskClub raised Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, January 9th. Nomura assumed coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued a “buy” rating and a $57.00 price target for the company. Piper Jaffray Companies assumed coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued an “overweight” rating and a $35.00 price target for the company. Instinet assumed coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued a “buy” rating and a $57.00 price target for the company. Finally, JMP Securities assumed coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued an “outperform” rating and a $38.00 price target for the company. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $40.83.

Deciphera Pharmaceuticals (NASDAQ DCPH) opened at $24.38 on Monday. The stock has a market capitalization of $794.59 and a P/E ratio of -6.16. Deciphera Pharmaceuticals has a fifty-two week low of $15.15 and a fifty-two week high of $26.59.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings results on Tuesday, November 14th. The company reported ($5.85) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($5.30). research analysts predict that Deciphera Pharmaceuticals will post -2.91 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in shares of Deciphera Pharmaceuticals in the third quarter valued at approximately $143,000. FNY Managed Accounts LLC acquired a new stake in shares of Deciphera Pharmaceuticals in the third quarter valued at approximately $153,000. Pura Vida Investments LLC acquired a new stake in shares of Deciphera Pharmaceuticals in the third quarter valued at approximately $1,329,000. Sphera Funds Management LTD. acquired a new stake in shares of Deciphera Pharmaceuticals in the third quarter valued at approximately $1,424,000. Finally, Perceptive Advisors LLC acquired a new stake in shares of Deciphera Pharmaceuticals in the third quarter valued at approximately $1,946,000. 43.94% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Zacks Investment Research Downgrades Deciphera Pharmaceuticals (DCPH) to Hold” was originally posted by Week Herald and is owned by of Week Herald. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://weekherald.com/2018/01/17/zacks-investment-research-downgrades-deciphera-pharmaceuticals-dcph-to-hold.html.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply